Accelerate to discover

Back to filter

Related topics

Early immune response in mice immunized with inactivated vaccine against SARS-CoV-2

Cytek Biosciences

Nov 19, 2020

The development of a vaccine against COVID-19 is a hot topic for many research laboratories all over the world. Our aim...

Bruker announces software provider PMOD Technologies LLC

Bruker Biospin

Nov 13, 2020

PMOD Technologies aims to equip researchers with best-in-class software tools for biomedical imaging research in humans...

Microvascular injury in mild traumatic brain injury accelerates alzheimer-like pathogenesis in mice

RWD

Nov 9, 2020

Traumatic brain injury (TBI) is considered as the most robust environmental risk factor for Alzheimer’s disease (AD)....

Discover the new NovoCyte Penteon - when exceptional performance meets simplicity

Agilent technologies

Nov 6, 2020

The NovoCyte Penteon flow cytometer builds on its successful predecessor, the NovoCyte. You now have the flexibility to...

Nov 23, 2020

Live animal imaging - Humane animal research

Bruker Biospin

Oct 26, 2020

Drawing on over 50 years of expertise in the life and animal sciences, Bruker designs preclinical imaging systems that...

Meet the Expert - Brent Barre interview

emka TECHNOLOGIES

Oct 21, 2020

Learn what a researcher at the forefront of COVID-19 research has to say about his current research environment.

Easy and accurate cell counting in less than 20 seconds with C100 counter

RWD

Oct 16, 2020

Cell counters are tools for counting live and/or dead cells in a culture. Any researcher who works in a cell culture...

Nov 23, 2020

Automated fever & hypothermia detection

emka TECHNOLOGIES

Oct 14, 2020

As one of the oldest clinical indicators of disease in mammals, temperature is a crucial parameter to monitor,...

Show all topics (10)

Better antibody discovery using IntelliCyt’s iQue Screener

May 18, 2016

With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.

Read more

 

Scientific paper
Product news

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

IntelliCyt

IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey